Navigation Links
New Drug for Rheumatoid Arthritis Looks Promising.

Patients with rheumatoid arthritis hopes have been raised with Roche announcing that its new drug showed positive results and was safe without any side effects according to its key study. Drug maker Roche Holding AG will file the drug Actemra for regulatory approval in Europe and the U.S. later this year.

Actemra was developed by Japanese pharmaceutical company Chugai Pharmaceutical Co. (4519.TO), which is controlled by Roche. Roche owns the rights to market Actemra outside Japan.

Two other drugs rituximab (Rituxan), abatacept (Orencia) are already there to reduce signs and symptoms of RA, improve physical function and health status, and slow joint damage progression.

Sufferers of rheumatoid arthritis, or RA, begin to experience progressive joint damage early in the disease. The disease differs from what is popularly known as arthritis, typically associated with age-related joint pain; RA is a far more serious inflammatory disease that leads to destruction of cartilage and bone, and can lead to disability.

The new treatment option Actemra in combination with traditional drugs achieved a significant improvement in disease signs and symptoms after 24 weeks, compared to those treated with the traditional drugs alone.

The heterogeneity of the disease is one of the reasons why no single therapy is effective for all patients or for one patient at all times. Disease-modifying anti-rheumatic drugs such as the anti-tumor necrosis factor (TNF) agents etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira), in combination with methotrexate, have significant anti-inflammatory and joint-protecting activity.

Abatacept, rituximab, and tocilizumab all achieved better clinical results in combination with methotrexate than when used as monotherapy.

Currently available drugs that target a protein called tumour necrosis factor, or TNF, have helped revolutionise treatment for rheum atoid arthritis, but up to 40 percent of patients do not get an adequate response. TNF blockers can also have significant side effects, including serious infections, tuberculosis and increased cancer risk.

"If active disease prevails despite anti-TNF treatment, rituximab or abatacept constitute novel alternatives, although abatacept could be administered before use of a TNF inhibitor (such practice is not currently licensed in Europe). The minimum therapeutic aim is low disease activity, but remission should constitute the ultimate goal." said Josef S. Smolen, M.D., of the Medical University of Vienna, and colleagues.


'"/>




Related medicine news :

1. New treatment for Rheumatoid Arthritis
2. New Rheumatoid Arthritis Treatment
3. New Rheumatoid Arthritis Treatment
4. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
5. The Link Between Rheumatoid Arthritis And Heart Failure
6. Smoking during pregnancy increases risk of Rheumatoid Arthritis.
7. Good News For Those Of You Suffering From Rheumatoid Arthritis
8. Mineral Oil exposure increases risk of Rheumatoid Arthritis
9. Mineral Oil exposure increases risk of Rheumatoid Arthritis
10. Novel drug holds promise for treatment of Rheumatoid Arthritis
11. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Orbita’s Nathan ... Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: Technology ... Home Event hosted by Parks Associates, a market research and consulting firm specializing ...
(Date:5/23/2017)... ... May 23, 2017 , ... Patients in need of a pulpotomy ... schedule an appointment, with or without a referral. Dr. Cotey is a respected dental ... patients as a healthy alternative to a tooth extraction. , When a child has ...
(Date:5/22/2017)... MO (PRWEB) , ... May 22, 2017 , ... Today, ... in Washington, MO with a public ribbon cutting ceremony. Since opening over ... offering an alternative to the emergency room. The new Our Urgent Care walk-in ...
(Date:5/22/2017)... ... May 22, 2017 , ... Faithfully following pop culture, people today are ... toned and shaped through fitness programs. It carries on to skin nourished, pampered and ... an irresistible, radiant smile. CDA has found that just like a perfectly ...
(Date:5/21/2017)... Dallas, Texas (PRWEB) , ... May 19, 2017 ... ... country, is pleased to announce the appointment of James (Jim) Vertino as Chief ... Vertino is a proven, transformational leader who drives innovation and business performance. He ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)...  Amy Baxter MD, chief executive officer and founder ... relief, was awarded a 2017 Top 40 Healthcare Transformer ... at the MM&M Top 40 Healthcare Transformers dinner and ... on May 10, 2017. The dinner followed a full-day ... the pill."  "Innovation goes beyond invention," noted ...
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
(Date:5/10/2017)... GLEN BURNIE, Md. , May 10, 2017 /PRNewswire/ ... and retention solutions for the clinical research industry, is ... website, www.CSSiEnroll.com . The new website features both ... better overall user experience and enhances the company,s already ... in the industry. "After many months ...
Breaking Medicine Technology: